Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibodyCombination of SON-1010 with anti-PD1 increased survival